Astrana Health to Buy Prospect Health for $745M

Dow Jones11-08

By Dean Seal

 

Astrana Health has agreed to buy the businesses and assets of Prospect Health for $745 million and the assumption of certain liabilities.

The healthcare company said Friday that it is acquiring the full Prospect Health System, which includes Prospect's licensed healthcare service plan in California and medical groups in California, Texas, Arizona and Rhode Island.

Astrana is also taking on Prospect's management service organization, the RightRx pharmacy and Alta Newport Hospital, an acute care hospital in California better known as Foothill Regional. Prospect is expected to generate revenue of about $1.2 billion in 2024, along with about $81 million in adjusted Ebitda.

Astrana is funding the acquisition with cash on hand and a $1.1 billion bridge loan from Truist Bank and J.P. Morgan.

The deal is expected to close in the middle of next year, pending regulatory approval.

Prospect is a tenant of Medical Properties Trust, which said Friday that the Astrana acquisition includes the assumption of certain liabilities but didn't go into further detail.

The real estate investment trust said it stands to receive about $200 million in proceeds from the Astrana acquisition, with most of that coming in the first half of 2025 and about $50 million expected by 2027.

Medical Properties Trust reported third-quarter results on Thursday and said Prospect hadn't paid cash rent related to six California properties.

Prospect was attempting to exit multiple east coast markets that were generating losses and impacting overall liquidity, including in Pennsylvania and Rhode Island, the real estate investment trust said.

 

Write to Dean Seal at dean.seal@wsj.com

 

(END) Dow Jones Newswires

November 08, 2024 08:50 ET (13:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment